COSCIENS Biopharma Inc - CSCI Company Long-Term Liabilities

Graphic logo of COSCIENS Biopharma Inc (CSCI)

COSCIENS Biopharma Inc. (CSCI) develops orphan drugs, monetizing its intellectual property through licensing agreements with global behemoths to generate royalties without the capital expenditures associated with manufacturing plants. This chart reflects the asset value fixed at 0.00. The business relies on expansion in Latin America and Canada, growing its portfolio of ophthalmology and oncology treatments by acquiring rights from biotech startups.

CSCI COSCIENS Biopharma Inc.: Company Long-Term Debts in the range 08/10/2024 - 09/14/2025

Analytical breakdowns for Aeterna Zentaris (CSCI)

- price and consensus price forecast:
Market Price cosciensbio.com|CSCI - Analyst Consensus Forecast
- market capitalization data:
Market Valuation COSCIENS Biopharma|CSCI - Enterprise Value
- book capitalization data:
Net Assets per Share COSCIENS Biopharma|CSCI - Book Capitalization|Market Capitalization to Book Value Ratio cosciensbio.com|CSCI - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity COSCIENS Biopharma Inc.|CSCI - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient COSCIENS Bio|CSCI - Company Total Debt|Debts to Book Capitalization Ratio COSCIENS Biopharma|CSCI - Company Long-Term Debts|Short-Term Debt COSCIENS Biopharma
Basic company analysis:CSCI (cosciensbio.com)
Original product of COSCIENS Biopharma Inc.

Long-term debt reflects the aggregate of obligations with a maturity exceeding one year, determining the sustainability of financial leverage. This metric measures a business's ability to service capital expenditures without the risk of default. By analyzing the firm's long-term borrowing values on GURU.Markets, an investor assesses the pace of credit load accumulation. For COSCIENS Biopharma Inc. (CSCI), this indicator is critical when scaling its licensing model in Latin America. Debt optimization confirms the effectiveness of the exclusive partnership strategy with global biopharma.

Direct competitors

Long-Term Debt vrtx.com VRTX|ALNY: Company Long-Term Debts|INSM - Company Long-Term Liabilities|United Therapeutics Corp. - Company Long-Term Debts|BioMarin Corp (BMRN) - Long-Term Debt Volume|BBIO (BridgeBio Pharma, Inc.) - Company Long-Term Debts|Company Long-Term Debts BGM|Company Long-Term Debt Cogent Biosciences, Inc. (COGT)|Company Long-Term Debt Xeris Biopharma Holdings, Inc. (XERS)|Company Long-Term Debts KROS|ARCT - Long-Term Debt Volume|Company Long-Term Liabilities Eton Pharmaceuticals|KMDA - Long-Term Liabilities|Company Long-Term Debts FULC|Abeona Therapeutics Inc. (ABEO) - Long-Term Debt|Company Long-Term Debts Mereo BioPharma Group (MREO)|Company Long-Term Indebtedness Protalix BioTherapeutics, Inc (PLX)|Pliant Therapeutics (PLRX) - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings APLT (Applied Therapeutics Inc.)|Rein Therapeutics (RNTX) - Company Long-Term Debt|Long-Term Liabilities Gelteq Ltd GELS|Company Long-Term Debts Aytu Therapeutics (AYTU)|CMMB - Company Long-Term Loans and Borrowings|SRXH: Company Long-Term Debts|PLRZ (Polyrizon) - Company Long-Term Debts|AEZS - Company Long-Term Debt|Company Long-Term Loans and Borrowings CYTH|Company Long-Term Debt INZY (Inozyme Pharma, Inc.)|Company Long-Term Liabilities Reneo Pharmaceuticals, Inc (RPHM)